AI assistant
Sending…
BridgeBio Pharma, Inc. — Director's Dealing 2021
Oct 27, 2021
30604_dirs_2021-10-26_629815a6-ae45-4274-b1c1-e4673405311d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2021-10-23
Reporting Person: Valantine Hannah (Director)
More from BridgeBio Pharma, Inc.
Regulatory Filings
2026
May 13
Regulatory Filings
2026
May 8
Interim / Quarterly Report
2026
May 7
Regulatory Filings
2026
May 7
Annual Report
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Director's Dealing
2026
Mar 20
Director's Dealing
2026
Mar 20
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Feb 27